iCAD announces compelling data supporting Profound AI breast cancer risk assessment

Auction Alert - Premier Medical Depot - Closing Dec 2nd - Bid on Over 365 Lots

iCAD announces compelling data supporting Profound AI breast cancer risk assessment

Press releases may be edited for formatting or style | September 15, 2020 Women's Health
NASHUA, N.H. – September 15, 2020 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced compelling data supporting ProFound AI™ Risk was published in the peer-reviewed journal, Radiology. ProFound AI Risk is the first and only commercially available clinical decision support tool that provides an accurate two-year breast cancer risk estimation that is personalized for each woman, based solely on a screening mammogram. The technology, which allows for the detection of cancers between screenings, was clinically proven to significantly outperform existing breast cancer risk models.

ProFound AI Risk was created from an exclusive relationship between iCAD and leading researchers at the Karolinska Institutet in Stockholm, Sweden, one of the world’s foremost medical research universities and the home of the Nobel Assembly, which selects the Nobel laureates in Physiology or Medicine. This partnership built upon a previous research agreement whereby researchers at the Karolinska Institutet developed a breast cancer risk prediction model using information identified in mammography images provided by iCAD’s AI solutions.

“ProFound AI Risk and the publication of this supporting study represent a giant leap forward in the realm of breast cancer screening. This first-in-kind solution provides crucial data about patients’ individual risk of developing breast cancer between screenings and empowers clinicians to truly personalize patient care,” according to Michael Klein, Chairman and CEO of iCAD. “This technology may help clinicians tailor unique screening regimens for patients, within country guidelines, and may help reduce unnecessary supplemental screenings for women with low risk.”

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

ProFound AI Risk software uniquely combines aspects within mammographic images, as well as age and breast density, to provide a highly accurate short-term risk estimation that is specific to each woman. The technology provides clinicians with a two-year breast cancer risk category [low, general, moderate and high] and absolute breast cancer risk score for each patient, based on information garnered from a standard bilateral two-view full field digital mammogram.

“ProFound AI empowers women to participate and advocate for the management of their breast care. There is a growing demand among patients to know more information about their individual risk. According to a recent survey, 87% of women expressed interest in learning about their estimated lifetime risk of breast cancer,” according to Stacey Stevens, President of iCAD. “ProFound AI Risk has the potential to revolutionize the way breast cancer risk is assessed and could contribute to the acceleration of breast cancer screening from what has historically been an aged-based screening paradigm to a risk-adapted screening paradigm, unique to each woman.”

You Must Be Logged In To Post A Comment